Navigation Links
FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
Date:12/10/2009

the choice of the adult FAP patient population, selection of cohort size, the dosing regimen, and duration of treatment. The trial is designed to determine safety and tolerability of CEQ508, starting with a dose-escalation phase in which patients will be given one of four escalating concentrations of the drug, contingent upon safety monitoring. This initial part of the clinical trial is expected to take approximately six months. Next, following a safety review, the trial plan calls for a stable-dose phase in which additional patients will receive the highest safe dose. The FDA will permit daily dosing of 18 or more patients for 28 days. A key readout and secondary objective of the trial includes analysis of biomarker beta-catenin expression changes in the gastrointestinal tract of patients determined from biopsy samples obtained prior to taking the drug and at the end of the dosing period.

Cequent's Vice President of Drug Development, Alison Silva, commented, "I want to commend the reviewers at CBER who have been very responsive, providing critical feedback immediately following our submission and throughout the application process. They worked with us so that we could address their questions quickly and effectively to reach a successful conclusion by our action date."

With the FDA approval of Cequent's clinical-trial protocol now in hand, the company has begun working with the proposed clinical center to obtain the necessary institutional approvals. Cequent expects to begin the Phase I clinical trial during the first quarter of 2010 at the Fred Hutchinson Cancer Research Center in Seattle, Washington, part of the Fred Hutchinson/University of Washington Cancer Consortium. The Cancer Consortium maintains a registry of FAP patients and is also one of 40 National Cancer Institute-designated comprehensive cancer centers nationwide. Gideon Steinbach, M.D., Ph.D., is slated to be the principal investigator (PI) of the Cequent trial. Dr. Steinbach is
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
2. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
3. U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
4. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
5. Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
6. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
7. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
8. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
11. Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Israel ... Israel 2013 , Israel,s 1 st ... October 14 th -15 th in Tel ... most innovative city in the world by the Wall ... BrainTech Israel 2013 will showcase the latest breakthroughs ...
(Date:5/23/2013)... -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ) (Intercept), ... and commercialization of novel bile acid therapeutics to treat ... announced that Mark Pruzanski , MD, ... Deutsche Bank Securities 38th Annual Health Care Conference in ... 2013 at 4:10 p.m. ET. About Intercept ...
(Date:5/23/2013)... 23, 2013  MedVantx, Inc., the company that has ... announced today the Company has completed a major expansion ... pharmaceutical products and the upgrade of its systems to ... in its specialty home delivery pharmacy in ... pharmaceutical manufacturers, physicians, health systems and payors novel distribution ...
Breaking Medicine Technology:Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3
(Date:5/23/2013)... -- Mayo Clinic researchers have used next generation genomic ... prostate cancer tumors have similar genetic origins, which may ... today in the journal Cancer Research . , ... using next generation sequencing in adjacent Gleason patterns in ... changes in pathology," says ,John Cheville, M.D., Mayo Clinic ...
(Date:5/23/2013)... 23, 2013 Transvaginal mesh lawsuit ... continue to move forward in a federal multidistrict litigation ... Virginia, Bernstein Liebhard LLP reports. In an Order ... by C.R. Bard to seal emails that included supplier ... other confidential, proprietary information about its suppliers. The emails ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 The ... a great deal of control over their level of ... weight, yet far fewer are actually taking that control. ... Food Information Council (IFIC) Foundation’s 2013 Food & Health ... respondents say it’s possible to have “a great deal ...
(Date:5/23/2013)... On April 29th, 2013, UV Technologies ... of H7N9 cases and deaths. The headline read, " UV ... Subside in Northern Hemisphere as Available Daylight Increases .” In ... reported. , Quoting Kevin McGuire, president of UV Technologies, ... budding in the spring and leaves changing in the fall. ...
(Date:5/23/2013)... Cheap Concert Tickets announces that Paul McCartney ... stadiums throughout North America. This well known ticket website ... tickets to help McCartney fans see Sir Paul live in ... that she is also offering the customer appreciation code SAVE ... baby boomer, she is also a huge McCartney fan and ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 2Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 3Health News:Paul McCartney Tickets: Prices Slashed on Paul McCartney Tickets in Austin, Brooklyn, Tulsa, Memphis Washington DC, Milwaukee, Boston, Indianapolis, Regina and Seattle 2
... 19 Healthcare,Technologies Ltd. (NASDAQ: HCTL ), announced ... scheduled for September 30,2007, will be held on December ... Arnon & Co., 1 Azrieli Center, Round Tower, 47th ... be asked to approve the previously,announced Asset Purchase Agreement ...
... may lower sperm count" do not tell the whole ... from the Harvard,School of Public Health in Boston presented ... was based on recollected intake,of soyfoods and not on ... issues, thus I feel the results should be viewed ...
... 18 West Pharmaceutical,Services, Inc. (NYSE: WST ... that it has decided to discontinue marketing the,Exubera ... the,Company,s customer, Nektar Therapeutics, Inc. The Company,s Tech ... Exubera inhalation device for Nektar. "We were ...
... Blocks inflammatory activity of two immune system molecules, researchers ... new twist on an old theory of drug treatment ... trial, a California company reports. , The idea is ... believed to play a major role in asthma by ...
... Republican Whip,Roy Blunt (Mo.) issued the following statement today ... the State,Children,s Health Insurance Program (SCHIP) to children from ... "Today,s vote brings to a close what,s been a ... their energy to scoring,political points, and none of it ...
... 18 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI;,TSX: QLT) ... of,privately held ForSight Newco II, Inc. Through this ... to commercialize,ForSight Newco II,s proprietary ocular punctal plug ... development efforts in this program. "We are ...
Cached Medicine News:Health News:Healthcare Technologies Announces New Date for the Shareholders Meeting to Approve the Nexgen Biofuels Transaction 2Health News:Healthcare Technologies Announces New Date for the Shareholders Meeting to Approve the Nexgen Biofuels Transaction 3Health News:Real Men Eat Soy: The Truth about Soy and Sperm Count 2Health News:West Pharmaceutical Services Issues Statement on Exubera 2Health News:West Pharmaceutical Services Issues Statement on Exubera 3Health News:West Pharmaceutical Services Issues Statement on Exubera 4Health News:New Drug Eases Asthma Symptoms 2Health News:New Drug Eases Asthma Symptoms 3Health News:QLT Completes Acquisition of ForSight Newco II, Inc. 2Health News:QLT Completes Acquisition of ForSight Newco II, Inc. 3
... multichannel pipettes speed up ... into microplates, with super ... volumes. The improved ergonomic ... multichannels, combined with super ...
... The Research pro Electronic Pipette is ... the laboratory. Its easy-to-follow display, ergonomically-placed operating ... pipetting, dispensing, reverse pipetting and diluting make ... the simple functions of a manual pipette ...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
... best value in high performance electronic pipetting!, ... design reduce hand fatigue and strain , ... ejector , Color coding for easy volume ... greater performance use Hamilton AdvanTip Low Retention ...
Medicine Products: